Insulin Aspart vs Linaclotide
Head-to-head comparison of Insulin Aspart (Insulin aspart (B28-Asp human insulin analog)) and Linaclotide (Linaclotide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Insulin Aspart | Linaclotide |
|---|---|---|
| Category | Diabetes & Metabolic | Gastrointestinal |
| Full Name | Insulin aspart (B28-Asp human insulin analog) | Linaclotide |
| Molecular Weight | 5825.8 Da | 1526.8 Da |
| Half-Life | About 1-3 hours | Active locally; negligible systemic half-life |
| Amino Acids | 51 | 14 |
| Typical Dose | 0.05-0.2 U/kg per meal | 72-290 mcg once daily |
| Route | Subcutaneous | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 11000 | 1200 |
| Research Status | Approved | Clinical |
Insulin Aspart Benefits
- ✓Fast post-meal glucose lowering
- ✓Predictable onset
- ✓Flexible mealtime administration
- ✓Compatible with pump therapy
Linaclotide Benefits
- ✓improves-bowel-movements
- ✓reduces-abdominal-pain
- ✓increases-intestinal-secretion
- ✓supports-transit
Insulin Aspart Dosing
Inject SC immediately before meals|Titrate using glucose monitoring and carbohydrate intake|Can be used in insulin pumps or basal-bolus regimens
Linaclotide Dosing
72 mcg PO daily|145 mcg PO daily|290 mcg PO daily
Insulin Aspart Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Linaclotide Side Effects
- ⚠diarrhea
- ⚠abdominal-pain
- ⚠bloating
Research Overview
Insulin Aspart
Research consistently shows faster onset and earlier peak action than regular human insulin. It is commonly studied for meal-time glycemic control and pump-based insulin delivery.
Linaclotide
Linaclotide has extensive clinical evidence for chronic idiopathic constipation and IBS-C, with consistent effects on stool frequency and abdominal symptom relief. Its mechanism is local GC-C activation in the gut with minimal systemic exposure.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.